Here are four things to know.
1. If elected, Dr. Noseworthy would join the board next month, replacing C. Robert Kidder.
2. As a board member, he would receive $110,000 in compensation and $170,000 in deferred stock from Merck annually, according to the report.
3. Dr. Noseworthy already sits on Mayo Clinic’s executive board and serves as a health governor for the World Economic Forum. A spot on Merck’s board would represent his first major leadership position in the private sector, according to the report.
4. To avoid potential conflicts on interest, Dr. Noseworthy would recuse himself from any Mayo decisions involving Merck, Mayo Clinic officials said.
More articles on leadership:
7 must-reads for healthcare leaders this week
Gallup: Americans cite healthcare as second most important problem facing US
Week in review: 12 biggest healthcare stories this week
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.